Protagonist Therapeutics, Inc Increase (Decrease) in Accounts Payable, Related Parties
Protagonist Therapeutics, Inc (PTGX) reported Increase (Decrease) in Accounts Payable, Related Parties of -$3.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-02-25.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableRelatedParties · last filed 2026-02-25
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for the quarter ending 2024-12-31 was $0.00.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for the quarter ending 2024-09-30 was $0.00.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for the quarter ending 2023-12-31 was $0.00, a 100.00% decline year-over-year.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for the quarter ending 2023-09-30 was -$7.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for fiscal 2024 was -$3.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for fiscal 2023 was -$66.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for fiscal 2022 was -$830.00K.
- Protagonist Therapeutics, Inc increase (decrease) in accounts payable, related parties for fiscal 2021 was -$1.83M, a 224.61% decline from fiscal 2020.
| Period end | Increase (Decrease) in Accounts Payable, Related Parties 3 month | Increase (Decrease) in Accounts Payable, Related Parties 6 month | Increase (Decrease) in Accounts Payable, Related Parties 9 month | Increase (Decrease) in Accounts Payable, Related Parties 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $0.00 derived: sum of 2 quarters · filed 2026-02-25 | -$3.00K 10-K · filed 2026-02-25 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$3.00K 10-Q · filed 2025-11-06 | ||
| 2024-06-30 | -$3.00K 10-Q · filed 2025-08-06 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | -$7.00K derived: sum of 2 quarters · filed 2026-02-25 | -$19.00K derived: sum of 3 quarters · filed 2026-02-25 | -$66.00K 10-K · filed 2026-02-25 |
| 2023-09-30 | -$7.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$19.00K derived: sum of 2 quarters · filed 2024-11-07 | -$66.00K 10-Q · filed 2024-11-07 | -$29.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-06-30 | -$12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$59.00K 10-Q · filed 2024-08-06 | -$22.00K derived: sum of 3 quarters · filed 2025-02-21 | -$70.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2023-03-31 | -$47.00K 10-Q · filed 2024-05-07 | -$10.00K derived: sum of 2 quarters · filed 2025-02-21 | -$58.00K derived: sum of 3 quarters · filed 2025-02-21 | -$358.00K derived: sum of 4 quarters · filed 2025-02-21 |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | -$11.00K derived: sum of 2 quarters · filed 2025-02-21 | -$311.00K derived: sum of 3 quarters · filed 2025-02-21 | -$830.00K 10-K · filed 2025-02-21 |
| 2022-09-30 | -$48.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$348.00K derived: sum of 2 quarters · filed 2023-11-02 | -$867.00K 10-Q · filed 2023-11-02 | -$1.09M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | -$300.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$819.00K 10-Q · filed 2023-08-03 | -$1.04M derived: sum of 3 quarters · filed 2024-02-27 | -$11.32M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | -$519.00K 10-Q · filed 2023-05-04 | -$741.00K derived: sum of 2 quarters · filed 2024-02-27 | -$11.02M derived: sum of 3 quarters · filed 2024-02-27 | -$6.44M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | -$222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$10.50M derived: sum of 2 quarters · filed 2024-02-27 | -$5.92M derived: sum of 3 quarters · filed 2024-02-27 | -$1.83M 10-K · filed 2024-02-27 |
| 2021-09-30 | -$10.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$5.70M derived: sum of 2 quarters · filed 2022-11-08 | -$1.61M 10-Q · filed 2022-11-08 | -$955.00K derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $4.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $8.66M 10-Q · filed 2022-08-04 | $9.32M derived: sum of 3 quarters · filed 2023-03-15 | $10.39M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | $4.09M 10-Q · filed 2022-05-05 | $4.75M derived: sum of 2 quarters · filed 2023-03-15 | $5.82M derived: sum of 3 quarters · filed 2023-03-15 | $5.71M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | $656.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $1.73M derived: sum of 2 quarters · filed 2023-03-15 | $1.62M derived: sum of 3 quarters · filed 2023-03-15 | $1.47M 10-K · filed 2023-03-15 |
| 2020-09-30 | $1.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-03 | $961.00K derived: sum of 2 quarters · filed 2021-11-03 | $815.00K 10-Q · filed 2021-11-03 | $1.06M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | -$113.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | -$259.00K 10-Q · filed 2021-08-04 | -$17.00K derived: sum of 3 quarters · filed 2022-02-28 | $193.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | -$146.00K 10-Q · filed 2021-05-04 | $96.00K derived: sum of 2 quarters · filed 2022-02-28 | $306.00K derived: sum of 3 quarters · filed 2022-02-28 | -$95.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $242.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $452.00K derived: sum of 2 quarters · filed 2022-02-28 | $51.00K derived: sum of 3 quarters · filed 2022-02-28 | $201.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $210.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$191.00K derived: sum of 2 quarters · filed 2020-11-04 | -$41.00K 10-Q · filed 2020-11-04 | $256.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-06-30 | -$401.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$251.00K 10-Q · filed 2020-08-06 | $46.00K derived: sum of 3 quarters · filed 2021-03-10 | $534.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2019-03-31 | $150.00K 10-Q · filed 2020-05-07 | $447.00K derived: sum of 2 quarters · filed 2021-03-10 | $935.00K derived: sum of 3 quarters · filed 2021-03-10 | $832.00K derived: sum of 4 quarters · filed 2021-03-10 |
| 2018-12-31 | $297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-10 | $785.00K derived: sum of 2 quarters · filed 2021-03-10 | $682.00K derived: sum of 3 quarters · filed 2021-03-10 | $1.06M 10-K · filed 2021-03-10 |
| 2018-09-30 | $488.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $385.00K derived: sum of 2 quarters · filed 2019-11-06 | $764.00K 10-Q · filed 2019-11-06 | |
| 2018-06-30 | -$103.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $276.00K 10-Q · filed 2019-08-07 | ||
| 2018-03-31 | $379.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |